NEW YORK (dpa-AFX Broker) - Analyst Jefferies left its rating on Fresenius at "buy" with a price target of 35 euros. Analyst James Vane-Tempest addressed investor reaction to his recent upgrade of Fresenius and downgrade of Fresenius Medical Care (FMC) in a research note issued Tuesday. Among investors, a spinoff of dialysis subsidiary FMC appears to be most popular, he wrote. Some believe that FMC's net income floor has not yet been reached, he said. In addition, investors viewed hospital operator subsidiary Helios as a core company of the medical group./edh/la

Publication of the original study: 09.01.2023 / 16:58 / ET

First disclosure of the original study: 09.01.2023 / 19:00 / ET

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------